MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that Chief Scientific Officer Thomas Hofmann will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29, 2022, at 8:00 AM PT. The company specializes in developing inhaled therapeutic products for endocrine and orphan lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only FDA-approved inhaled ultra-rapid-acting mealtime insulin available in the U.S. by prescription.

DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas Hofmann, MD, PhD, will participate in the Cantor Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am (PT).

If you have interest in participating in the Cantor Virtual Rare Orphan Disease Summit, please reach out to your Cantor Fitzgerald representative.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Company Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

 

FAQ

What event will MannKind Corporation's Chief Scientific Officer participate in?

Thomas Hofmann will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29, 2022.

What is MannKind Corporation known for?

MannKind Corporation focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases.

What is Afrezza and how is it utilized?

Afrezza is an inhaled ultra-rapid-acting mealtime insulin developed by MannKind, available by prescription in the U.S. and Brazil.

When was MannKind Corporation established?

MannKind Corporation was established in 1991.

How can one participate in the Cantor Virtual Rare Orphan Disease Summit?

Interested parties can reach out to their Cantor Fitzgerald representative to participate.